CTNI-67. EFFICACY AND SAFETY OF LAROTRECTINIB IN PATIENTS WITH TROPOMYOSIN RECEPTOR KINASE (TRK) FUSION PRIMARY CENTRAL NERVOUS SYSTEM (CNS) TUMORS: AN EXPANDED DATASET

BACKGROUND: TRK fusion proteins are oncogenic drivers of various CNS and non-CNS tumors. Larotrectinib, a highly selective FDA- and EMA-approved TRK inhibitor, demonstrated an objective response rate (ORR) of 79% across various non-CNS cancers (Hong et al. Lancet Oncol. 2020). We report data in an e...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Neuro Oncol
Main Authors: Perreault, Sébastien, Doz, François, Drilon, Alexander, Geoerger, Birgit, Boni, Valentina, Chisholm, Julia, Dubois, Steven G, Grilley-Olson, Juneko E, Hong, David S, Italiano, Antoine, Kang, HyoungJin, Nysom, Karsten, Øra, Ingrid, Owens, Cormac, Schulte, Johannes H, Tahara, Makoto, Ziegler, David, Ellezam, Benjamin, Reeves, John A, Fellous, Marc, De La Cuesta, Esther, Laetsch, Theodore W, van Tilburg, Cornelis M
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2020
Teme:
Clinical Trials: Non-Immunologic
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7651037/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa215.233
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki